Figure 5 from Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor–Resistant Head and Neck Squamous Cell Carcinoma

Signaling changes induced by treatment with VIC-1911 and adavosertib in parental, AfaR, and ErlR HNSCC models. A–E, Representative Western blots and quantification for phospho-CDK1 (Y15) and total-CDK1 (A), γH2AX (S139; B), TPX2 (C), total AURKA (D), and NEDD9 (E) in FaDu parental, ErlR, and AfaR cell models treated with DMSO, VIC-1911 (0.25 μmol/L), adavosertib (0.5 μmol/L), or combination for 24 hours. A and B share the same loading control, as they were derived from the same gel. Bar graphs display data normalized to the DMSO of each cell line. P values are based on one-way ANOVA followed by the Tukey multiple comparison test. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. Data are shown as mean ± SEM of three biological replicates.